News

South African pharmaceutical company Aspen Pharmacare on Tuesday announced its deal with the American firm Johnson & Johnson to jointly manufacture its COVID-19 vaccine candidate ‘Ad26.COV3-S’. The manufacture of the vaccine is subject to its approval internationally and in...

German vaccine maker CureVac on Monday said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers. The vaccine candidate was generally well tolerated across all tested doses...

The number of cases of the coronavirus disease (Covid-19) is nearing the 50 million mark across the world and the death toll has risen to more than 1.2 million, according to a worldometers tally, even as the global hunt...

Pierre-Alain Ruffieux today joins Lonza Group in the role of Chief Executive Officer. Albert Baehny has taken the role of CEO ad interim since November 2019. He will now work with Pierre-Alain to ensure a smooth handover of leadership...

Novartis and Molecular Partners AG announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to...

Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc. announced the expansion of a long-term manufacturing partnership for Checkpoint’s anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug...

Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein. A rapidly reemerging tick-borne disease, POWV has been reported to be fatal in 10%...